Resveratrol for Cardiovascular Disease
Verdict: Published with Warning
Across 5 PubMed studies, the evidence for Resveratrol in Cardiovascular Disease grades Tier C — weak evidence. Effective, but with safety or population caveats.
C 🟠 C Weak Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.57
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
78%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.574
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (5)L2 · primary research & systematic reviews
Anti-inflammatory effects of resveratrol in patients with cardiovascular disease: A systematic review and meta-analysis of RCTs
Finding: Resveratrol significantly reduced CRP (MD=-0.63, p=0.01) and TNF-α (MD=-0.55, p=0.02); no significant effect on IL-6 (p=0.53).
View on PubMed Resveratrol supplementation efficiently improves endothelial health: A systematic review and meta-analysis of randomized controlled trials
Finding: Resveratrol significantly improved FMD (WMD +1.43%, p<0.001) and reduced ICAM-1 (WMD -7.09 ng/mL, p<0.001); no significant change in VCAM-1, fibrinogen, or PAI-1.
View on PubMed Usefulness of resveratrol supplementation in decreasing cardiometabolic risk factors: meta-analysis of multinational, randomised, controlled trials
Finding: In metabolic syndrome patients: significant reductions in HOMA-IR (MD -0.521, p=0.001), glucose (MD -1.069, p=0.043), LDL-C (MD -0.924, p=0.040), and total cholesterol (MD -1.246, p=0.022); benefits largely confined to MetS subgroup.
View on PubMed Effect of resveratrol supplementation on biomarkers associated with atherosclerosis in humans
Finding: Higher doses (~454 mg/day) for shorter durations produced greater TG and BP reductions; lower doses (~274 mg/day) for longer durations (175 days) produced the highest HDL increase; results dose- and duration-dependent with high heterogeneity.
View on PubMed Resveratrol improves lipid profile and recovers heart function in postoperative CABG patients
Finding: Resveratrol significantly reduced SBP, TG, total cholesterol, and LDL, and improved ejection fraction vs. placebo in post-CABG patients (p values not reported in abstract).
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Cautious
At the notifier's request, FDA ceased to evaluate this notice source↗
L4b EU EFSA
Cautious
L4d TW TFDA / 衛福部
Neutral
訂定「以基因改造啤酒酵母(Saccharomyces cerevisiae) EFSC4687菌株發酵生產之食品原料反式白藜蘆醇(trans-resveratrol)之使用限制及標示規定」，並自即日生效。限用於供成人使用之膳食補充品，每日攝取量上限為150毫克。本產品限供成人使用，孕婦及授乳者應避免食用；服用藥物者須諮詢醫師方可使用。 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
Study results on resveratrol are mixed — some research shows that resveratrol may reduce blood clots and inflammation to lower heart disease risk, but other studies have found that resveratrol does not protect against heart disease, and more research is needed. Research suggests that the body can't absorb most of the resveratrol in supplements. source↗
L5c Cleveland Clinic
Cautious
L5d Harvard Health
Against
L5e Specialty Society (condition-mapped)
Cautious